Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review

被引：0
|
作者：
Jiejin Zhu
Ying Zhou
Qingyu Li
Gang Wang
机构：
[1] Zhejiang University School of Medicine,Department of Clinical Pharmacy, Affiliated Hangzhou First People’s Hospital
[2] Zhejiang University School of Medicine,Department of Pharmacy, Affiliated Hangzhou Cancer Hospital
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Cost-effectiveness; Dipeptidyl peptidase 4 inhibitor; Glucagon-like peptide 1 receptor agonist; Second-line treatment; Sodium-glucose transporter 2 inhibitor; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4216 / 4235
页数：19
相关论文
共 50 条
  • [1] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Zhu, Jiejin
    Zhou, Ying
    Li, Qingyu
    Wang, Gang
    [J]. ADVANCES IN THERAPY, 2023, 40 (10) : 4216 - 4235
  • [2] Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
    Franchi, Matteo
    Pellegrini, Giacomo
    Avogaro, Angelo
    Buzzetti, Giuliano
    Candido, Riccardo
    Cavaliere, Arturo
    Consoli, Agostino
    Marzona, Irene
    Mennini, Francesco Saverio
    Palcic, Stefano
    Corrao, Giovanni
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (03)
  • [3] Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review
    Holdt-Caspersen, Nynne Sophie
    Dethlefsen, Claus
    Vestergaard, Peter
    Hejlesen, Ole
    Hangaard, Stine
    Jensen, Morten Hasselstrom
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (02):
  • [4] COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT
    Tan, E. C. H.
    Yang, M. C.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S52 - S53
  • [5] Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas
    Genere, Natalia
    Montori, Victor M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) : JC8 - JC8
  • [6] Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
    Reifsnider, Odette S.
    Pimple, Pratik
    Brand, Sarah
    Washington, Evelien Bergrath
    Shetty, Sharash
    Desai, Nihar R.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 652 - 661
  • [7] Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
    Gu, Shuyan
    Zeng, Yuhang
    Yu, Demin
    Hu, Xiaoqian
    Dong, Hengjin
    [J]. PLOS ONE, 2016, 11 (11):
  • [8] A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Henrik Vitus Bering Laursen
    Emmelie Ploug Jørgensen
    Peter Vestergaard
    Lars Holger Ehlers
    [J]. PharmacoEconomics, 2023, 41 : 1469 - 1514
  • [9] A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Laursen, Henrik Vitus Bering
    Jorgensen, Emmelie Ploug
    Vestergaard, Peter
    Ehlers, Lars Holger
    [J]. PHARMACOECONOMICS, 2023, 41 (11) : 1469 - 1514
  • [10] Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    [J]. CIRCULATION, 2019, 140
12345